Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. reduced its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 26.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,810 shares of the company's stock after selling 8,447 shares during the period. Edgestream Partners L.P. owned about 0.08% of Krystal Biotech worth $3,730,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $15,989,000. Arizona State Retirement System increased its holdings in Krystal Biotech by 8.5% in the fourth quarter. Arizona State Retirement System now owns 6,242 shares of the company's stock valued at $978,000 after buying an additional 487 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Krystal Biotech by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company's stock worth $38,095,000 after acquiring an additional 2,954 shares during the period. US Bancorp DE boosted its stake in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after acquiring an additional 82 shares in the last quarter. Finally, Illinois Municipal Retirement Fund grew its position in shares of Krystal Biotech by 11.9% during the 4th quarter. Illinois Municipal Retirement Fund now owns 14,146 shares of the company's stock valued at $2,216,000 after acquiring an additional 1,505 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.

Remove Ads

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company's stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company's stock.

Krystal Biotech Stock Performance

KRYS traded down $6.49 during trading on Wednesday, hitting $178.39. The stock had a trading volume of 263,090 shares, compared to its average volume of 291,190. The firm has a market capitalization of $5.14 billion, a P/E ratio of 59.66 and a beta of 0.87. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34. The company's 50-day moving average price is $162.22 and its 200 day moving average price is $174.16.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. During the same period in the prior year, the company posted $0.30 earnings per share. The firm's revenue for the quarter was up 116.4% on a year-over-year basis. As a group, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Chardan Capital increased their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Citigroup raised their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Finally, Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech has a consensus rating of "Buy" and an average target price of $220.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).